GeNeuro announces completion of recruitment of its long-COVID Phase 2 trial and confirms top-line results for June 2024
Geneva, Switzerland, November 28, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the completion of the […]